Skin responses to bradykinin, kallidin, and [desArg9]-bradykinin in nonatopic and atopic volunteers

What Was Tested

The paper reports a study of Bradykinin, published as a randomized controlled trial.

Kinins are potent vasoactive oligopeptides that may act as mediators in a variety of inflammatory diseases of the skin by interacting with specific receptors designated B1 and B2.

In this study the researchers have investigated the structure-activity relationship of intradermally injected bradykinin, kallidin (lysine-bradykinin), and [desArg9]-bradykinin in atopic (n = 8) and nonatopic (n = 8) subjects.

Who Took Part

PubMed indexes the participants as adults, both men and women.

In a separate randomized double-blind study the researchers have also examined the effect of an orally administered antihistamine, terfenadine, on kinin-induced wheal and flare responses and their repeatability in a group of nine volunteers.

The skin responses were monitored objectively by measurement of wheal and flare areas.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Bradykinin could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Bradykinin, Hypersensitivity, Hypersensitivity, Immediate, Injections, Intradermal, Kallidin and Skin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1993 (The Journal of allergy and clinical immunology), a journal based in United States.

More context: the Bradykinin compound page, all human trials.